Article Text

Download PDFPDF
Interplay of inflammation, oxidative stress and cardiovascular disease in rheumatoid arthritis
  1. Marco Del Buono1,2,
  2. Antonio Abbate1,
  3. Stefano Toldo1
  1. 1 VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA
  2. 2 Department of Cardiovascular Medicine, Catholic University, Rome, Italy
  1. Correspondence to Dr Stefano Toldo, VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 1220, USA; stefano.toldo{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rheumatoid arthritis (RA) is a chronic autoimmune/autoinflammatory disorder characterised by a symmetric erosive polyarthritis, with an additive and progressive evolution leading to joint deformities and bone anchyloses. The prevalence is about 1% of the general population, and its presence is associated to a marked increased risk of cardiovascular death, particularly due to coronary artery disease (CAD) and heart failure (HF).1 RA occurs in postmenopausal women and middle-age men who often have the traditional cardiovascular risk factors; however, such risk factors cannot fully account for the increased risk observed in these patients. A combined interaction of cytokine spillover, oxidative stress, abnormal innate and specific immune adaptation and coagulation abnormalities have been considered as potential mechanisms of increased cardiovascular risk.2Systemic cytokines (especially interleukin-1β (IL-1β), interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α)) and inflammatory biomarkers (such as C reactive proteins) are directly associated with the severity of CAD and the risk of atherothrombotic events.2 Patients with RA also have an increased risk of develop non-ischaemic HF.3 The underlying pathophysiological mechanisms are far from being completely …

View Full Text


  • Contributors MDB drafted the initial version. AA revised the first and the revised versions. ST reviewed and approved the final version and the illustration.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AA and ST have received research support and/or served as a consultant to Novartis, Olatec and Swedish Orphan Biovitrum.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles